Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Solventum shares have traded sideways post-spin, as investors digest separation impacts, stranded costs, and recent capital allocation moves. Despite a $4.1B divestment and targeted $500M cost savings, 2025 results showed minimal free cash flow and only modest earnings growth. 2026 guidance calls for 2-3% organic sales growth and adjusted EPS of $6.50, but free cash flow remains weak at ~$200M.
SOLV's Q4 earnings and revenues beat estimates, driven by organic growth across MedSurg, Dental and HIS, despite margins declined.
| Software Industry | Information Technology Sector | Bryan C. Hanson CEO | XDUS Exchange | US83444M1018 ISIN |
| US Country | 22,000 Employees | - Last Dividend | - Last Split | - IPO Date |
Solventum Corporation is a cutting-edge healthcare company established in 2023 and headquartered in Saint Paul, Minnesota. Specializing in the development, manufacture, and commercialization of diverse solutions aimed at addressing urgent customer and patient needs, the company operates across four main segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. Solventum Corporation stands out in the healthcare industry by offering a wide-ranging portfolio of innovative products and services, demonstrating its commitment to improving healthcare outcomes and enhancing the efficiency of medical and dental professions.